Document Detail


Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation.
MedLine Citation:
PMID:  11069209     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We evaluated the technical robustness of the new commercial TBII assay using human recombinant TSH-R, and describe its use for the clinician in the routine laboratory. The human recombinant TSH-R assay (DYNOtest TRAK human) was compared to a conventional TBII assay (TSH-REZAK). Specificity was adjusted at 99.1% for both assays by ROC plot analysis including 113 healthy individuals. Sensitivity in 115 patients with active Graves' Disease (GD) was 98.2% for the DYNOtest TRAK human compared to 68.4% for the TSH-REZAK (p<0.0001). Comparison of the ROC-calculated cut off confirmed the recommended cut-off for the DYNOtest TRAK human, since 11% inhibition of tracer equals 1 IU/L, which is recommended as the grey zone. At the recommended cut-off (2 IU/L, 22% inhibition), the sensitivity is still 93.9% with 100% specificity. The ROC plot-derived cut-off of the TSH-REZAK (4.4%, 2 to 10 U/L) is below the grey zone of 10-15 U/L. At the recommended cut off of 15 U/L, the sensitivity is 43.0% with a specificity of 100%. Both assays showed a good correlation (r = 0.82, p < 0.0001); however, assay comparison revealed a constant bias in favour of the DYNOtest TRAK human. Applying the ROC plot-derived cut-off of 11 % inhibition (1 IU/L) for the DYNOtest TRAK human, we found 15 of 50 patients with autoimmune thyroiditis (AIT) and 6 of 23 patients with goitre (all < 1.5 IU/L). These patients would have been missed using the recommended 2 IU/L. The difference in sensitivity between the DYNOtest TRAK human and the TSH-REZAK was highly significant in the GD group, but not in other groups, indicating that the DYNOtest TRAK human has a higher sensitivity for GD without compromising specificity. In summary, the proposed high sensitivity of the new TBII assay using human recombinant TSH-R could be confirmed with the commercial product. This method offers a clear advantage over conventional TBII assays to confirm or exclude the diagnosis of GD. The recommended cut-off is very stringent, and until we have more information on the clinical relevance of low-level TBII between 1 and 1.5 IU/L, those patients should be monitored for the development of autoimmune thyroid disease.
Authors:
M Schott; J Feldkamp; C Bathan; R Fritzen; W A Scherbaum; J Seissler
Related Documents :
3923949 - High doses of antigen-nonspecific igg do not inhibit pemphigus acantholysis in skin org...
1472629 - Assessment of antibody dependent cell cytotoxicity in autoimmune thyroid disease using ...
15286419 - Spectrum of anti-neutrophil cytoplasmic antibodies in patients with pulmonary tuberculo...
8296619 - Significance of autoantibodies to purified proteinase 3 in systemic vasculitis.
20477159 - Pathogenic mechanisms of anti-neutrophil cytoplasm antibody-associated vasculitis.
7694219 - Investigation of antigenic determinants in thyroid peroxidase by synthesis of possible ...
15705479 - Programming of ctl with heat-killed brucella abortus and antigen allows soluble antigen...
2525559 - Alteration by heat shock and immunological characterization of drosophila small nuclear...
8896219 - Analysis of monoclonal antibodies reactive with molecules upregulated or expressed only...
Publication Detail:
Type:  Clinical Trial; Evaluation Studies; Journal Article    
Journal Detail:
Title:  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme     Volume:  32     ISSN:  0018-5043     ISO Abbreviation:  Horm. Metab. Res.     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2001-03-06     Completed Date:  2001-05-31     Revised Date:  2009-02-19    
Medline Journal Info:
Nlm Unique ID:  0177722     Medline TA:  Horm Metab Res     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  429-35     Citation Subset:  IM    
Affiliation:
Department of Endocrinology, Heinrich-Heine-University, Düsseldorf, Germany. schottmt@uni-duesseldorf.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Autoantibodies / analysis*
Binding Sites / immunology
Follow-Up Studies
Graves Disease / diagnosis*,  radiotherapy,  surgery
Humans
Iodine Radioisotopes / therapeutic use
Receptors, Thyrotropin / immunology*
Recombinant Proteins / diagnostic use
Reference Values
Reproducibility of Results
Thyroiditis, Autoimmune / diagnosis*,  radiotherapy,  surgery
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Iodine Radioisotopes; 0/Receptors, Thyrotropin; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and t...
Next Document:  Effect of norethisterone acetate on estrogen metabolism in postmenopausal women.